Angela V. Hafner, Director of External Innovation at Agenus, shared a post on LinkedIn:
“Thrilled to share an exciting milestone from our External Innovation efforts at MiNK Therapeutics!
Our PRAME-targeted iNKT cell therapy program has been selected as one of the first programs by C-Further since the consortium’s launch.
Through this collaboration, the program will receive up to ~$1.1M in non-dilutive funding to support IND-enabling development, along with the potential for meaningful double-digit downstream commercial revenue participation.
This partnership reflects a shared commitment to advancing innovative, well-tolerated immunotherapies for children with cancers that currently have limited treatment options, and highlights how creative translational funding models and strong external innovation collaborations can accelerate promising science toward the clinic.
Incredibly grateful to the outstanding teams at MiNK Therapeutics and C-Further for the collaboration, vision, and dedication to bringing new therapeutic options to patients. Excited for what comes next!
Other articles on Immunotherapy.